Valuation: Arecor Therapeutics plc

Market Cap 22.47M 30.44M 26.29M 24.7M 42.24M 2.91B 42.93M 289M 113M 1.46B 114M 112M 4.84B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 21.15M 28.65M 24.74M 23.25M 39.75M 2.74B 40.41M 272M 107M 1.37B 108M 105M 4.56B EV / Sales 2026 *
24.1x
EV / Sales 2027 * 24.4x
Free-Float
46.91%
Yield 2026 *
-
Yield 2027 * -
1 week+3.48%
Current month-2.46%
1 month-6.30%
3 months-9.85%
6 months-17.93%
Current year-26.09%
1 week 56.2
Extreme 56.2
65
1 month 55.27
Extreme 55.266
65
Current year 55.27
Extreme 55.266
95
1 year 55.27
Extreme 55.266
100
3 years 35.4
Extreme 35.4
199
5 years 35.4
Extreme 35.4
472
10 years 35.4
Extreme 35.4
472
Manager TitleAgeSince
Chief Executive Officer 51 12/04/2021
Director of Finance/CFO - 17/11/2024
Chief Tech/Sci/R&D Officer - 31/07/2007
Director TitleAgeSince
Director/Board Member 51 12/04/2021
Director/Board Member 61 31/08/2017
Chairman 66 12/04/2021
Date Insider Type Main position Quantity % Market Cap.
04/06/25 Free

Executive/Senior Manager

85,000 0.2251%
04/06/25 Free

Chief Technology Officer

85,000 0.2251%
04/06/25 Free

Chief Executive Officer

66,000 0.1748%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+3.48%-6.30%-69.09% 30.44M
-1.78%-1.68%+1.99%+13.84% 48.42B
+0.85%-0.70%+465.55%+579.03% 43.66B
-2.40%-0.23%+12.20%+70.22% 39.51B
-2.01%-0.85%+24.95%+7.51% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
-0.59%-2.06%+26.13%+117.79% 16.15B
+0.38%-3.23% - - 16.32B
+0.49%+0.92%+4.32%+22.16% 14.16B
-0.43%+4.70%+79.75%+29.11% 13.37B
Average -0.60%+0.79%+69.91%+91.14% 26.32B
Weighted average by Cap. -0.91%+0.59%+97.62%+134.66%

Financials

2026 *2027 *
Net sales 878K 1.19M 1.03M 966K 1.65M 114M 1.68M 11.32M 4.43M 56.99M 4.47M 4.37M 189M 1.05M 1.42M 1.23M 1.15M 1.97M 136M 2.01M 13.53M 5.29M 68.12M 5.34M 5.22M 226M
Net income - -
Net Debt -1.32M -1.79M -1.54M -1.45M -2.48M -171M -2.52M -17M -6.65M -85.62M -6.71M -6.57M -285M 3.2M 4.34M 3.75M 3.52M 6.02M 415M 6.12M 41.27M 16.13M 208M 16.29M 15.94M 691M
Logo Arecor Therapeutics plc
Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its in-house development programs include AT278, Oral GLP-1 and AT247. AT278 is its ultra-concentrated, ultra-rapid acting insulin candidate. AT278 is designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). AT247 is designed to accelerate the absorption of insulin post injection. It is focused on the development of an oral GLP-1 receptor agonist (semaglutide). It has partnered with TRx Biosciences, combining its Arestat technology and TRx Biosciences' lipid technology, Lipicore, to target improved bioavailability of an oral GLP-1 receptor agonist. Its partnered programs include AT220, AT292 and AT351.
Employees
33
Date Price Change Volume
14/08/26 GBX 59.50 0.00% 95,461
13/08/26 GBX 59.50 0.00% 77,968
12/08/26 GBX 59.50 0.00% 2,048
11/08/26 GBX 59.50 +1.71% 19,000
10/08/26 GBX 58.50 +1.74% 69,400
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.5950GBP
Average target price
2.755GBP
Spread / Average Target
+363.03%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AREC Stock